Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) just unveiled an announcement.
Shandong Xinhua Pharmaceutical Company Limited has received approval from the National Medical Products Administration for its Sacubitril Valsartan Sodium, a drug used to treat chronic heart failure and essential hypertension. This approval marks a significant step for the company, potentially enhancing its market position in the pharmaceutical industry by expanding its product offerings and addressing critical health needs.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a pharmaceutical company based in China, focusing on the production and marketing of chemical substance drugs. The company is involved in the healthcare industry, primarily producing medications for various health conditions.
Average Trading Volume: 4,484,342
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.71B
See more data about 0719 stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue